Skip to main content

Table 6 Comparison of treatment outcome, based on an immediate NPV ratio of 80%, between groups 1 and 2

From: Volumetric magnetic resonance-guided high-intensity focused ultrasound ablation of uterine fibroids through abdominal scars: the impact of a scar patch on therapeutic efficacy and adverse effects

Treatment outcome Group 1 Group 2
  ≥80%
(n = 12)
<80%
(n = 5)
P value ≥80%
(n = 40)
<80%
(n = 6)
P value
Fibroid volumea
 Baseline    0.208    0.765
  Mean ± SD 214.9 ± 200.0 94.2 ± 33.7   171.3 ± 137.0 152.7 ± 173.6  
  Range 37.0–794.0 51.0–143.0   6.0–637.0 12.0–478.0  
 6 months    0.925    0.057
  Mean ± SD 88.8 ± 79.8 85.2 ± 36.2   83.1 ± 71.0 167.5 ± 215.1  
  Range 11.0–295.0 41.0–140.0   4.0–400.0 10.0–578.0  
 Reduction ratio (6 months)    0.001*    0.001*
  Mean ± SD 0.6 ± 0.15 0.11 ± 0.11   0.49 ± 0.13 0.03 ± 0.16  
  Range 0.25–0.8 −0.03–0.2   0.22–0.84 −0.21–0.18  
Symptom severity scoreb
 Baseline    0.916    0.155
  Mean ± SD 54.7 ± 14.4 55.6 ± 21.0   51.6 ± 16.1 62.0 ± 17.7  
  Range 31.2–75.0 31.2–87.5   21.9–84.4 43.7–93.7  
 6 months    0.001*    0.001*
  Mean ± SD 4.2 ± 5.0 46.2 ± 16.9   6.2 ± 7.5 47.9 ± 31.8  
  Range 0.0–15.6 18.7–62.5   0.0–37.5 6.2–100.0  
 Improvement ratio (6 months)    0.001*    0.001*
  Mean ± SD 0.93 ± 0.8 0.15 ± 0.27   0.88 ± 0.14 0.25 ± 0.36  
  Range 0.75–1.0 −0.2–0.43   0.5–1.0 −0.07–0.89  
  1. SD standard deviation
  2. aLargest treated fibroid only
  3. bTransformed symptom severe score (SSS) can range from 0 to 100
  4. *Statistically significant